ROCKVILLE, Md., Aug. 10, 2009 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF) (“the Company”), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today reported financial results for the three and six months ended June 30, 2009.
